A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).
Caroline Robert
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Roche
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Paolo Antonio Ascierto
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; MedImmune; MSD; Novartis; Roche/Genentech
Honoraria - Bristol-Myers Squibb; MSD; Roche/Genentech
Michele Maio
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Micaela Hernberg
Consultant or Advisory Role - Bristol-Myers Squibb
Other Remuneration - Bristol-Myers Squibb
Henrik Schmidt
Consultant or Advisory Role - Bristol-Myers Squibb; Roche
Honoraria - Bristol-Myers Squibb; Roche
Ian Waxman
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Claus Garbe
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Philogen; Roche; SOBI
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Philogen; Roche; SOBI
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Roche; SOBI
Céleste Lebbé
Consultant or Advisory Role - Roche
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Expert Testimony - Roche (U)
Axel Hauschild
Consultant or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche